Linked Life Data

15921806

Source:http://linkedlifedata.com/resource/pubmed/id/15921806

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-5-30
pubmed:abstractText
The Carvedilol or Metoprolol European Trial (COMET) reported a significant survival benefit for carvedilol, a beta1-, beta2- and alpha1-blocker, vs. metoprolol tartrate, a beta1-selective blocker, in patients with mild-to-severe chronic heart failure (CHF). Patients on treatment with metoprolol might benefit from switching to carvedilol.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1388-9842
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
640-9
pubmed:dateRevised
2011-6-8
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
pubmed:affiliation
Department of Cardiology, Ospedale di Cattinara, Strada di Fiume 447, 34100 Trieste, Italy. dilenar@univ.ts.it
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't